Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | HSP-CAR30 |
| Synonyms | |
| Therapy Description |
HSP-CAR30 is a chimeric antigen receptor (CAR) T-cell therapy targeting CD30 that is enriched for memory T-cells, which has potential antitumor activtiy (Blood (2022) 140 (Supplement 1): 405-407). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| HSP-CAR30 | HSP CAR30|HSPCAR30 | CD30 (TNFRSF8) Immune Cell Therapy 5 | HSP-CAR30 is a chimeric antigen receptor (CAR) T-cell therapy targeting CD30 that is enriched for memory T-cells, which has potential antitumor activtiy (Blood (2022) 140 (Supplement 1): 405-407). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT04653649 | Phase Ib/II | HSP-CAR30 | CAR T-cells Against CD30 (HSP-CAR30) for Relapsed/ Refractory Hodgkin and T-cell Lymphoma. | Unknown status | ESP | 0 |